Diplomat Pharmacy (DPLO) PT Raised to $40 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Leerink Partners Maintains OP Following Diplomat Pharmacy (DPLO) Q1
May 12, 2015 11:14 AM EDTLeerink Partners maintains an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $40.00 (from $36.00), following the release on the 1Q15 results. Diplomat reported an adjusted EPS of $0.09 (+57% y/y), which was $0.01 ahead of Leerink estimates and consensus. Total revenue of $625M increased +34% y/y. Revenue was slightly ahead of Leerink estimate
but below consensus.
Leerink analyst, David Larsen, commented on the... More
Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
May 11, 2015 4:08 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $625 million versus the consensus estimate of $629.6 million.
Diplomat Pharmacy sees FY2015 EPS of $0.48-$0.51, versus prior guidance of $0.47-$0.50 and the consensus of... More
